Dr Reddy’s has announced the acquisition of the generic portfolio of Mayne Pharma in the US for $105m. The portfolio had sales of $111m in FY22 (ending Jun-22). Our preliminary analysis suggests that the product portfolio is plain vanilla as all the products are oral solid dosage (OSD) and many have high competitive intensity. However, […]
